title: Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
abstract: OBJECTIVE
  To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy.
  
  
  METHODS
  We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression.
  
  
  RESULTS
  Patients with ER/PgR-absent tumors were 12.0 times [95% confidence interval (CI) 4.93-29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95% CI 1.04-2.32, P = 0.03] and HER2 (HR 1.6, 95% CI 1.08-2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95% CI 1.41-2.99, P = 0.0002).
  
  
  CONCLUSIONS
  The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.
authors.affiliation: Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy. marco.colleoni@ieo.it
authors.forename: M
authors.initials: M
authors.lastname: Colleoni
authors.forename: G
authors.initials: G
authors.lastname: Viale
authors.forename: D
authors.initials: D
authors.lastname: Zahrieh
authors.forename: L
authors.initials: L
authors.lastname: Bottiglieri
authors.forename: R D
authors.initials: RD
authors.lastname: Gelber
authors.forename: P
authors.initials: P
authors.lastname: Veronesi
authors.forename: A
authors.initials: A
authors.lastname: Balduzzi
authors.forename: R
authors.initials: R
authors.lastname: Torrisi
authors.forename: A
authors.initials: A
authors.lastname: Luini
authors.forename: M
authors.initials: M
authors.lastname: Intra
authors.forename: S
authors.initials: S
authors.lastname: Dellapasqua
authors.forename: A
authors.initials: A
authors.lastname: Cardillo
authors.forename: R
authors.initials: R
authors.lastname: Ghisini
authors.forename: G
authors.initials: G
authors.lastname: Peruzzotti
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D011292:Premedication; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone